{"transactions":[{"id":747418,"issuer":{"id":3735,"kind":"organization","name":"CG Oncology, Inc.","symbol":"CGON"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-05T20:30:07.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":9354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":9354,"derivative":{"exercise_price":56.09,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":9354},"source":{"system":"sec-edgar","filing":"0001193125-26-259690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000119312526259690/ownership.xml","form_type":"4"}},{"id":986545,"issuer":{"id":3735,"kind":"organization","name":"CG Oncology, Inc.","symbol":"CGON"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-11-26T21:30:09.000Z","date":"2025-11-24","kind":"grant","planned":true,"acquired":true,"shares":20889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest monthly following November 24, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":20889,"derivative":{"exercise_price":43.56,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":20889},"source":{"system":"sec-edgar","filing":"0001193125-25-300645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000119312525300645/ownership.xml","form_type":"4"}},{"id":1083871,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.57,"underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083870,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":95.12,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083869,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":43.15,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083868,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083867,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":100.13,"underlying":"Common Stock","underlying_shares":26125},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083866,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":54.13,"underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083865,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":86.6,"underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083864,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":65.75,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083863,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":20628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083862,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82374,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions (\"PSUs\"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."}],"balance_after":20628,"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1083861,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-21T19:47:28.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":39456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions (\"PSUs\"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award."}],"balance_after":103002,"source":{"system":"sec-edgar","filing":"0001104659-25-069387","document":"tm2521348-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069387/tm2521348-16_4seq1.xml","form_type":"4"}},{"id":1090479,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-07-08T16:20:07.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":1172,"price":128.25,"value":150309.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":63546,"source":{"system":"sec-edgar","filing":"0001415889-25-019507","document":"form4-07082025_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925019507/form4-07082025_040703.xml","form_type":"4"}},{"id":1112812,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:34:52.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016964","document":"form4-06122025_080649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000141588925016964/form4-06122025_080649.xml","form_type":"4"}},{"id":1138647,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-21T16:33:04.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":57,"price":101.72,"value":5798.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $101.58 to $101.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":64718,"source":{"system":"sec-edgar","filing":"0001415889-25-013941","document":"form4-05212025_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925013941/form4-05212025_080500.xml","form_type":"4"}},{"id":1138646,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-21T16:33:04.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":1413,"price":100.67,"value":142246.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $100.42 to $101.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":64775,"source":{"system":"sec-edgar","filing":"0001415889-25-013941","document":"form4-05212025_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925013941/form4-05212025_080500.xml","form_type":"4"}},{"id":1138645,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-21T16:33:04.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":804,"price":100.14,"value":80512.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $99.42 to $100.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":66188,"source":{"system":"sec-edgar","filing":"0001415889-25-013941","document":"form4-05212025_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925013941/form4-05212025_080500.xml","form_type":"4"}},{"id":1155898,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-07T16:32:25.000Z","date":"2025-05-05","kind":"sale","planned":true,"acquired":false,"shares":144,"price":103.56,"value":14912.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $103.35 to $104.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":66992,"source":{"system":"sec-edgar","filing":"0001415889-25-012250","document":"form4-05072025_080520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925012250/form4-05072025_080520.xml","form_type":"4"}},{"id":1155897,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-07T16:32:25.000Z","date":"2025-05-05","kind":"sale","planned":true,"acquired":false,"shares":180,"price":102.82,"value":18507.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $102.34 to $103.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":67136,"source":{"system":"sec-edgar","filing":"0001415889-25-012250","document":"form4-05072025_080520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925012250/form4-05072025_080520.xml","form_type":"4"}},{"id":1155896,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-07T16:32:25.000Z","date":"2025-05-05","kind":"sale","planned":true,"acquired":false,"shares":1343,"price":101.77,"value":136677.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $101.33 to $102.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":67316,"source":{"system":"sec-edgar","filing":"0001415889-25-012250","document":"form4-05072025_080520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925012250/form4-05072025_080520.xml","form_type":"4"}},{"id":1155895,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-05-07T16:32:25.000Z","date":"2025-05-05","kind":"sale","planned":true,"acquired":false,"shares":607,"price":100.97,"value":61288.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $100.32 to $101.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":68659,"source":{"system":"sec-edgar","filing":"0001415889-25-012250","document":"form4-05072025_080520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925012250/form4-05072025_080520.xml","form_type":"4"}},{"id":1190607,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-03-26T16:27:48.000Z","date":"2025-03-24","kind":"sale","planned":true,"acquired":false,"shares":2274,"price":95.02,"value":216075.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $95.00 to $95.06. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":69266,"source":{"system":"sec-edgar","filing":"0001415889-25-009027","document":"form4-03262025_080345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925009027/form4-03262025_080345.xml","form_type":"4"}},{"id":1216853,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-03-07T16:14:16.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":6495,"price":88.8,"value":576756.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":71540,"source":{"system":"sec-edgar","filing":"0001415889-25-007404","document":"form4-03072025_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925007404/form4-03072025_090313.xml","form_type":"4"}},{"id":1226440,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T17:18:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":26400,"derivative":{"exercise_price":96.57,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001415889-25-006605","document":"form4-03042025_100345.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925006605/form4-03042025_100345.xml","form_type":"4"}},{"id":1226439,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-03-04T17:18:48.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 13,200 restricted stock units under the Issuer's 2024 Stock Incentive Plan."}],"balance_after":78035,"source":{"system":"sec-edgar","filing":"0001415889-25-006605","document":"form4-03042025_100345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925006605/form4-03042025_100345.xml","form_type":"4"}},{"id":1248886,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T16:15:21.000Z","date":"2025-02-20","kind":"sale","planned":true,"acquired":false,"shares":2274,"price":95.14,"value":216348.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $95.00 to $95.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":64835,"source":{"system":"sec-edgar","filing":"0001415889-25-005244","document":"form4-02242025_090217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925005244/form4-02242025_090217.xml","form_type":"4"}},{"id":1296198,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-01-23T19:54:05.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":121,"price":111.81,"value":13529.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $111.45 to $112.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":67109,"source":{"system":"sec-edgar","filing":"0001415889-25-001991","document":"form4-01242025_120102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001991/form4-01242025_120102.xml","form_type":"4"}},{"id":1296197,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-01-23T19:54:05.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":808,"price":110.78,"value":89510.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $110.45 to $111.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":67230,"source":{"system":"sec-edgar","filing":"0001415889-25-001991","document":"form4-01242025_120102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001991/form4-01242025_120102.xml","form_type":"4"}},{"id":1296196,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-01-23T19:54:05.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":816,"price":110,"value":89760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $109.42 to $110.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":68038,"source":{"system":"sec-edgar","filing":"0001415889-25-001991","document":"form4-01242025_120102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001991/form4-01242025_120102.xml","form_type":"4"}},{"id":1296195,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2025-01-23T19:54:05.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":529,"price":108.99,"value":57655.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $108.37 to $109.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":68854,"source":{"system":"sec-edgar","filing":"0001415889-25-001991","document":"form4-01242025_120102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001991/form4-01242025_120102.xml","form_type":"4"}},{"id":1323873,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2024-12-20T16:15:08.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":108,"price":96.5,"value":10422.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":69383,"source":{"system":"sec-edgar","filing":"0001415889-24-029970","document":"form4-12202024_041204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029970/form4-12202024_041204.xml","form_type":"4"}},{"id":1323872,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2024-12-20T16:15:08.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":2166,"price":95.88,"value":207676.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price. The shares were sold in multiple transactions ranging from $95.44 to $96.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":69491,"source":{"system":"sec-edgar","filing":"0001415889-24-029970","document":"form4-12202024_041204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029970/form4-12202024_041204.xml","form_type":"4"}},{"id":1346862,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2024-12-02T18:52:46.000Z","date":"2024-11-27","kind":"sale","planned":true,"acquired":false,"shares":2274,"price":95.1,"value":216257.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 27, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average sale price.  The shares were sold in multiple transactions ranging from $95.01 to $95.21.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":71657,"source":{"system":"sec-edgar","filing":"0001415889-24-028012","document":"form4-12022024_111242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924028012/form4-12022024_111242.xml","form_type":"4"}},{"id":1458143,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2024-07-08T19:07:22.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":9625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 9,625 restricted stock units under Issuer's 2024 Stock Incentive Plan."}],"balance_after":73931,"source":{"system":"sec-edgar","filing":"0001415889-24-019390","document":"form4-07082024_110718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924019390/form4-07082024_110718.xml","form_type":"4"}},{"id":1476808,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:30:12.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.02,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-017206","document":"form4-06172024_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000141588924017206/form4-06172024_040607.xml","form_type":"4"}},{"id":1583547,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2024-03-11T18:21:14.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":6070,"price":90.69,"value":550488.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":64306,"source":{"system":"sec-edgar","filing":"0001415889-24-007556","document":"form4-03112024_100308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924007556/form4-03112024_100308.xml","form_type":"4"}},{"id":1590832,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T16:20:13.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2024 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":95.12,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-007016","document":"form4-03062024_090302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924007016/form4-03062024_090302.xml","form_type":"4"}},{"id":1590831,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2024-03-06T16:20:13.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 15,000 restricted stock units under the Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":70376,"source":{"system":"sec-edgar","filing":"0001415889-24-007016","document":"form4-03062024_090302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924007016/form4-03062024_090302.xml","form_type":"4"}},{"id":1856823,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T20:30:26.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":13200,"derivative":{"exercise_price":2.8,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001415889-23-009737","document":"form4-06132023_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000141588923009737/form4-06132023_040610.xml","form_type":"4"}},{"id":1962546,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2023-03-08T21:36:48.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":99,"price":44.28,"value":4383.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $43.83 to $44.39 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":55376,"source":{"system":"sec-edgar","filing":"0001415889-23-004565","document":"form4-03092023_020342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923004565/form4-03092023_020342.xml","form_type":"4"}},{"id":1962545,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2023-03-08T21:36:48.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":2960,"price":45.72,"value":135331.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":55475,"source":{"system":"sec-edgar","filing":"0001415889-23-004565","document":"form4-03092023_020342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923004565/form4-03092023_020342.xml","form_type":"4"}},{"id":1971640,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T20:07:00.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":43.15,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-23-004260","document":"form4-03042023_010339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923004260/form4-03042023_010339.xml","form_type":"4"}},{"id":1971639,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2023-03-03T20:07:00.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of grant of 15,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":58435,"source":{"system":"sec-edgar","filing":"0001415889-23-004260","document":"form4-03042023_010339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923004260/form4-03042023_010339.xml","form_type":"4"}},{"id":2123187,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2022-11-07T16:08:57.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":533,"price":45.24,"value":24112.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $45.11 to $45.24 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":43435,"source":{"system":"sec-edgar","filing":"0001415889-22-011112","document":"form4-11072022_091137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922011112/form4-11072022_091137.xml","form_type":"4"}},{"id":2226475,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:30:55.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date."}],"balance_after":13200,"derivative":{"exercise_price":2.28,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001415889-22-006745","document":"form4-06172022_040617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756941/000141588922006745/form4-06172022_040617.xml","form_type":"4"}},{"id":2319749,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-23T16:05:13.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":511,"price":110.85,"value":56644.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount of securities beneficially owned by the Reporting Person, as reported in Forms 4 filed by the Reporting Person subsequent to the Transaction Date but prior to the date of this Form 4, did not reflect this sell to cover transaction."}],"balance_after":43968,"source":{"system":"sec-edgar","filing":"0001415889-22-003280","document":"form4-03232022_040302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922003280/form4-03232022_040302.xml","form_type":"4"}},{"id":2343601,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-08T16:05:54.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":1047,"price":56.19,"value":58830.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $56.18 to $57.02 per share."}],"balance_after":44479,"source":{"system":"sec-edgar","filing":"0001415889-22-002739","document":"form4-03082022_040344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922002739/form4-03082022_040344.xml","form_type":"4"}},{"id":2343600,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-08T16:05:54.000Z","date":"2022-03-03","kind":"sale","acquired":false,"shares":1197,"price":60.28,"value":72155.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.27 to $60.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) to this Form 4."}],"balance_after":45526,"source":{"system":"sec-edgar","filing":"0001415889-22-002739","document":"form4-03082022_040344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922002739/form4-03082022_040344.xml","form_type":"4"}},{"id":2352765,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T20:08:51.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":61.31,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-22-002443","document":"form4-03032022_050336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922002443/form4-03032022_050336.xml","form_type":"4"}},{"id":2352764,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-03T20:08:51.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 15,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":46723,"source":{"system":"sec-edgar","filing":"0001415889-22-002443","document":"form4-03032022_050336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922002443/form4-03032022_050336.xml","form_type":"4"}},{"id":2805207,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T17:48:58.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":1272,"price":86.61,"value":110167.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":31723,"source":{"system":"sec-edgar","filing":"0001179110-21-003005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021003005/edgar.xml","form_type":"4"}},{"id":2805206,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T17:48:58.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":87,"price":89.1,"value":7751.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.08 to $89.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32995,"source":{"system":"sec-edgar","filing":"0001179110-21-003005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021003005/edgar.xml","form_type":"4"}},{"id":2811380,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T16:27:29.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":26125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":26125,"derivative":{"exercise_price":100.13,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":26125},"source":{"system":"sec-edgar","filing":"0001179110-21-002672","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021002672/edgar.xml","form_type":"4"}},{"id":2811379,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T16:27:29.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":13062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan."}],"balance_after":33082,"source":{"system":"sec-edgar","filing":"0001179110-21-002672","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021002672/edgar.xml","form_type":"4"}},{"id":2990799,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-11-05T17:02:02.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":345,"price":99.69,"value":34393.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":20020,"source":{"system":"sec-edgar","filing":"0001179110-20-010844","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020010844/edgar.xml","form_type":"4"}},{"id":3215022,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-11T16:27:55.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":135,"price":51.96,"value":7014.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":20365,"source":{"system":"sec-edgar","filing":"0001179110-20-003468","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020003468/edgar.xml","form_type":"4"}},{"id":3230684,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-03T19:11:52.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":28500,"derivative":{"exercise_price":54.13,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001179110-20-002965","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020002965/edgar.xml","form_type":"4"}},{"id":3230683,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-03T19:11:52.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of 14,250 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 14,250 newly awarded restricted stock units, 5,125 previously reported restricted stock units, 438 of which vested on March 1, 2020, and 1,125 shares of common stock."}],"balance_after":20500,"source":{"system":"sec-edgar","filing":"0001179110-20-002965","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020002965/edgar.xml","form_type":"4"}},{"id":3379742,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-11-05T16:16:51.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":1125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 1, 2018, the reporting person was granted 4,500 restricted stock units, vesting in four equal annual installments on November 1, 2019, 2020, 2021 and 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 1, 2018, the reporting person was granted 4,500 restricted stock units, vesting in four equal annual installments on November 1, 2019, 2020, 2021 and 2022."}],"balance_after":3375,"derivative":{"underlying":"Common Stock","underlying_shares":1125},"source":{"system":"sec-edgar","filing":"0001179110-19-011412","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019011412/edgar.xml","form_type":"4"}},{"id":3379741,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-11-05T16:16:51.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":1125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1125,"source":{"system":"sec-edgar","filing":"0001179110-19-011412","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019011412/edgar.xml","form_type":"4"}},{"id":3610570,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-03-05T17:24:36.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023."}],"balance_after":1750,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001179110-19-003306","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019003306/edgar.xml","form_type":"4"}},{"id":3610569,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-05T17:24:36.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":6500,"derivative":{"exercise_price":86.6,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001179110-19-003306","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911019003306/edgar.xml","form_type":"4"}},{"id":3773791,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-11-05T16:55:30.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in four equal annual installments on November 1, 2019, 2020, 2021 and 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in four equal annual installments on November 1, 2019, 2020, 2021 and 2022."}],"balance_after":4500,"derivative":{"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-18-012562","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018012562/edgar.xml","form_type":"4"}},{"id":3773790,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":40790,"kind":"person","name":"Rossi Christina","position":1,"cik":"0001756941","reported_name":"Rossi Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-05T16:55:30.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"In accordance with the Issuer's equity award grant policy, this option was granted effective as of the first day of the month following the commencement of the Reporting Person's employment with the Issuer on October 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 25% of the shares underlying the option on November 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter."}],"balance_after":80000,"derivative":{"exercise_price":65.75,"expiration_date":"2028-11-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001179110-18-012562","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911018012562/edgar.xml","form_type":"4"}}]}